Core Insights - GXO Logistics and Greene King have achieved significant sustainability milestones through their partnership, focusing on fleet decarbonisation, waste reduction, and community impact [1][2] Decarbonisation Efforts - Since 2019, GXO and Greene King have successfully reduced carbon intensity (gCO2e/km) through technology and behavioral changes, including trials of biodiesel, HVO, and electric vehicles, which can reduce emissions by up to 90% compared to diesel [3] Waste Reduction and Recycling - The partnership has effectively utilized GXO's reverse logistics capabilities, resulting in the elimination of over 160,000 journeys annually and recycling over 16,000 tonnes of waste in 2024 [1][4] - In 2024, Greene King expanded its recycling initiatives to include ink cartridges, batteries, correx boards, and crushed glass in London [4] Community Support - Over 90% of excess food at depots was donated to charities, leading to an estimated 240,000 meals donated in 2024 [5] - The Tub2Pub campaign collected over 240,000 confectionery tubs, raising more than £10,000 for Macmillan Cancer Support, with recycled plastic repurposed into furniture [8] Operational Efficiency - A structured driver performance management system improved fuel efficiency (MPG) by over 10% in 2024, while investments in Eco Drive hydro-electric refrigeration technology reduced fuel use by 2-4% since 2022 [6] - Energy consumption during deliveries was cut by up to 50% through the installation of strip and air curtains in refrigerated trailers [6] Material Recycling - The partnership has recycled significant quantities of materials, including over 2.7 million litres of used cooking oil, more than 4,000 tonnes of cardboard, 250+ tonnes of metal, 55+ tonnes of plastic, and 9,000+ tonnes of food waste sent to anaerobic digestion [7]

Core Insights - Arcutis Biotherapeutics is presenting new data on ZORYVE (roflumilast) efficacy for seborrheic dermatitis, atopic dermatitis, and psoriasis at the EADV Congress in Paris from September 17-20, 2025 [1] Efficacy of ZORYVE - ZORYVE foam 0.3% shows significant improvement in seborrheic dermatitis, with an Investigator Global Assessment (IGA) Success rate of 79.5% compared to 58.0% for the vehicle at Week 8 [5] - The treatment is effective across diverse populations, with similar efficacy observed among different races and ethnicities [5] - ZORYVE cream 0.05% demonstrates improved quality of life and reduced family impact in children aged 2-5 years with atopic dermatitis [4][6] - Both ZORYVE cream 0.3% and foam 0.3% improve signs and symptoms of plaque psoriasis in individuals with facial and/or genital involvement [7] Safety and Tolerability - ZORYVE foam 0.3% is well tolerated, with improvements in hypopigmentation and hyperpigmentation observed across all subgroups [5] - The treatment has shown minimal irritation at the application site in children, indicating good tolerability [6] Product Information - ZORYVE is the leading prescribed topical therapy for atopic dermatitis, seborrheic dermatitis, and plaque psoriasis [10] - The product is a selective phosphodiesterase-4 (PDE4) inhibitor, targeting inflammatory mediators [10] - ZORYVE cream 0.3% and foam 0.3% are FDA-approved for various age groups, with specific indications for plaque psoriasis and seborrheic dermatitis [11][12][13] Company Commitment - Arcutis Biotherapeutics emphasizes its commitment to advancing innovative therapies for inflammatory skin diseases, aiming to improve patient lives [9][17]

The valuation is based on recent transaction benchmarks and central rights rather than the sum of individual team values. “With the tenth team onboard, the league is now valued at close to Rs 500 crore,” said Tuhin Mishra, co-founder of PVL and Baseline Ventures. “Teams are valued between Rs 50–70 crore depending on performance and sponsorships.”Mishra said earlier projections of $90 million were “aspirational,” while actual deals were “closer to Rs 400–500 crore.” “Valuations were around Rs 400 crore when ...

Core Insights - The article emphasizes three companies—Waste Management, Intuitive Surgical, and Marriott International—as strong candidates for long-term investment due to their competitive advantages and stable cash flows [2][3]. Waste Management - Waste Management (WM) reported second-quarter revenue of approximately $6.4 billion, reflecting a 19% year-over-year increase, driven by solid performance in core operations and contributions from a healthcare disposal acquisition [5]. - The legacy disposal business saw a revenue increase of 7.1% year over year, indicating robust growth even without acquisitions [5]. - WM's management projects full-year free cash flow between $2.8 billion and $2.9 billion, significantly up from an initial guidance of $125 million, supporting dividends and buybacks while allowing for growth investments [6]. - The company's scale, route density, and long-term contracts create a competitive moat that is difficult for new entrants to penetrate [6]. Intuitive Surgical - Intuitive Surgical reported second-quarter revenue of about $2.44 billion, a 21% year-over-year increase, driven by higher placements of da Vinci systems and increased procedure volumes [9]. - The installed base of da Vinci systems grew at a double-digit rate, and management expects procedure growth of approximately 15.5% to 17% in 2025 [9][10]. - The company has a strong balance sheet with significant cash reserves and no debt, enhancing its resilience [12]. - Intuitive Surgical's price-to-earnings ratio is around 61, indicating that much of the potential upside is already reflected in the stock price [11]. Marriott International - Marriott International's second-quarter revenue per available room (RevPAR) increased by 1.5% year over year, with international markets growing by 5.3% [13]. - Non-GAAP earnings per share rose to $2.65, up from $2.50 in the previous year, and adjusted EBITDA reached approximately $1.4 billion, a 7% increase year over year [13]. - The company repurchased about $0.7 billion of stock during the quarter and has returned approximately $2.1 billion year to date through dividends and buybacks [13]. - Marriott's asset-light model, focusing on franchising and management rather than ownership, allows for low capital needs and strong cash conversion [14].

Core Viewpoint - The Federal Reserve is anticipated to cut interest rates due to internal disagreements over policy direction and an ongoing leadership transition [1] Group 1: Interest Rate Policy - The Fed's potential interest rate cut is influenced by differing opinions among policymakers regarding the current economic conditions and future outlook [1] - The leadership transition within the Fed is contributing to uncertainty in policy decisions, which may lead to a more accommodative monetary stance [1] Group 2: Economic Implications - A reduction in interest rates could stimulate economic growth by making borrowing cheaper for consumers and businesses [1] - The anticipated rate cut reflects concerns about economic slowdown and inflationary pressures, which may necessitate a shift in monetary policy [1]

Core Insights - The excitement surrounding forward stock splits in high-profile companies has significantly contributed to the S&P 500's performance in 2025, alongside the trend of artificial intelligence [1][2] Group 1: Stock Split Dynamics - A stock split allows companies to adjust their share price and outstanding share count without affecting market capitalization or operating performance [2] - Investors typically favor companies that announce forward splits, as these are perceived to make shares more affordable for retail investors [4] - Companies completing forward splits often demonstrate superior innovation and execution compared to their competitors [4] Group 2: Company Performances - O'Reilly Automotive has seen a 36% year-to-date increase, driven by a 15-for-1 forward split and strong demand for auto parts due to the aging vehicle population [5][6][7] - Fastenal's shares are up 32% year-to-date, benefiting from its corporate culture of frequent stock splits and strong ties to contract sales, which account for over 73% of its net revenue [11][14] - Interactive Brokers Group has outperformed with a 44% year-to-date increase, supported by a favorable stock market environment and significant investments in technology that enhance customer offerings [17][18][19][20]

Group 1 - The VanEck CLO ETF (CLOI) received a buy rating in July 2025 due to strong fundamentals in the CLO market, high yields, and defensive characteristics [1] - The analyst has a Master's in Banking & Finance and a diverse background in corporate finance, M&A, and investment analysis, focusing on real estate, renewable energy, and equity markets [1] - The analyst specializes in financial modeling, valuation, and qualitative analysis, with experience in private equity, asset management, and real estate [1] Group 2 - The article emphasizes the importance of sharing insights and analysis with a global audience to foster informed decision-making [1]

Core Insights - ALK has entered a partnership with Changchun GeneScience Pharmaceutical Co. Ltd. to develop and commercialize its house dust mite allergy immunotherapy products in Mainland China [2][3][10] - GenSci will have exclusive rights to ALK's Alutard HDM product, skin prick tests, and ACARIZAX SLIT-tablet until the end of 2039, while ALK will handle production and supply [3][10] - The partnership aims to accelerate market uptake of ALK's products in China, which has a significant number of individuals suffering from HDM allergies but low treatment penetration [6][10] Company Overview - ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma, headquartered in Hørsholm, Denmark, employing around 2,800 people [16] - GenSci is a leading biopharmaceutical company in China with over 9,000 employees, specializing in pediatric and women's health, and is involved in multiple therapeutic areas [17] Financial Implications - The partnership is not expected to materially impact ALK's revenue and earnings in 2025, but is projected to become accretive to earnings margin in the medium term due to savings on capacity costs and clinical expenses [9][10] - ALK will receive an upfront payment of approximately DKK 245 million and is eligible for milestone payments up to DKK 1.3 billion, which will be recognized as revenue over the partnership's duration [12][10] Strategic Goals - GenSci plans to allocate a significant sales force to promote ALK's products and engage in market-building activities, including education and collaborations with healthcare providers [6][10] - Both companies will explore collaboration on innovation for other allergic diseases, with GenSci focusing on the Chinese market and ALK on international markets [8]

PresentationJustin FurbyVice President of Investor Relations Hello. Thank you everybody. Welcome to Workday Rising. Welcome to Financial Analyst Day. This is our biggest conference ever. I don't know what the growth is, but I think it's pretty significant. I know this is our biggest Analyst Day event, which is good because this is by far the largest room that we've ever had. So thank you for not making it look too ridiculous and for showing up. We are glad that you made the trip out in all seriousness. Thi ...

Eli Lilly's international president Patrik Jonsson said on Wednesday the company had little clarity on the U.S. Food and Drug Administration's new fast-track review process, cautioning it was too earl... ...